BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Obecure Recruits First Patient in Phase II Obesity Study in Pre-Menopause Women


9/8/2008 8:59:34 AM

RAMAT GAN, Israel--(BUSINESS WIRE)--Obecure has commenced a Phase II clinical trial to evaluate the efficacy of HistaleanTM in obese patients. This study, encoded BET-207, is a follow-up to the Company's post-hoc findings in a prior Phase II study, suggesting that treatment with a 48 mg/day dose of the drug provides significant weight reduction in obese women up to the age of 50. The current study is a double-blinded, placebo-controlled, multi-center, dose ranging study to confirm the efficacy of a 12 week treatment with the drug in obese but otherwise healthy premenopausal females aged 18-50. The study will randomize about 180 obese women, with a body to mass ratio (BMI) ranging from 30 - 40 kg/m2, into three study arms: 60 women will be treated with 48 mg/day HistaleanTM, 60 women will be treated with 96 mg/day HistaleanTM and 60 women will receive matching placebo. The study will be carried out in about 12 investigation sites in Europe and regulatory approval has already been received in Belgium and the Netherlands.

Read at BioSpace.com

Obecure
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES